研究单位：[1]Boehringer Ingelheim[2]China-Japan Friendship Hospital,Beijing,China,100029[3]Beijing Tongren Hospital,Beijing,China,100730[4]The General Hospital of Chinese People's Armed Police Forces,Beijing,China,100854[5]First Hospital of Jilin University,Changchun,China,130021[6]No.900 Hospital of PLA Joint Logistics Support Force,Fuzhou,China,350025[7]Third Affiliated Hospital of Guangzhou Medical University,Guangzhou,China,510150[8]The Affiliated Hospital of Guizhou Medical University,Guiyang,China,550004[9]The Affiliated Hospital of Hangzhou Normal University,Hangzhou,China,310015[10]General Hospital of Jinan Military Area,Jinan,China,250000[11]Nanjing First Hospital,Nanjing,China,210006[12]The affiliated hospital of medicalcollege qingdao university,Qingdao,China,266005[13]Centre Hospital of Putuo District, Shanghai,Shanghai,China,200062[14]Shanghai Tenth People's Hospital,Shanghai,China,200072[15]Yangpu Hospital, Tongji University,Shanghai,China,200090[16]Second Hospital Affiliated to Shantou Medical University,Shantou,China,515041[17]Shengjing Hospital of China Medical University,Shengyang,China,110072[18]Siping Central People's Hospital,Siping,China,136000[19]The First Affiliated Hospital of Soochow University,Suzhou,China,215006[20]Nankai University Affiliated Hospital,Tianjin,China,300000[21]The 2nd Hospital of Tianjin Medical University,Tianjin,China,300000[22]Tianjin Medical University General Hospital,Tianjin,China,30052[23]Renmin Hospital of Wuhan University,Wuhan,China,430060[24]First Affiliated Hospital of Xiamen University,Xiamen,China,361003[25]the first people hospital of Yue Yang,Yueyang,China,414000[26]Affiliated Hospital of Jiangsu University,Zhenjiang,China,212013
研究目的：
To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control
